Medical note: This article is for educational purposes only and is not a substitute for diagnosis, treatment, or personalized medical advice from a qualified healthcare professional.
A pancreatic neuroendocrine tumor, often shortened to pancreatic NET or pNET, is a rare type of tumor that starts in the hormone-producing cells of the pancreas. It is not the same as the more common pancreatic cancer most people hear about, which usually begins in the pancreas’s exocrine cells. Think of the pancreas as a hardworking kitchen appliance with two jobs: it helps digest food and helps control blood sugar. A pancreatic neuroendocrine tumor starts in the part of the pancreas that handles the “chemical messaging” side of the business.
Because these tumors can behave very differently from person to person, they often feel confusing at first. Some grow slowly and are found by accident during a scan for something else. Others make extra hormones and cause dramatic symptoms that seem unrelated to the pancreas, such as low blood sugar, severe heartburn, diarrhea, flushing, or an unusual skin rash. In other words, pNETs can be quiet librarians or noisy alarm clocks. The tricky part is knowing which one you are dealing with.
The good news is that medical understanding of pancreatic NETs has improved significantly. Diagnosis, imaging, surgery, targeted therapy, somatostatin analogs, peptide receptor radionuclide therapy, liver-directed therapy, and long-term surveillance can all play a role depending on the tumor’s type, grade, stage, and behavior.
What Is a Pancreatic Neuroendocrine Tumor?
A pancreatic neuroendocrine tumor develops from neuroendocrine cells in the pancreas. These cells have features of nerve cells and hormone-producing endocrine cells. Their normal job is to help regulate body functions by releasing hormones into the bloodstream.
Pancreatic NETs are sometimes called islet cell tumors, although that older term is not always precise. They are considered rare compared with pancreatic adenocarcinoma, the most common type of pancreatic cancer. However, pancreatic NETs often have a better outlook, especially when found early, when they are low-grade, or when surgery can remove the tumor completely.
Types of Pancreatic Neuroendocrine Tumors
Doctors usually classify pancreatic neuroendocrine tumors in several ways. The most practical starting point is whether the tumor is functional or nonfunctional.
Functional Pancreatic NETs
A functional pancreatic NET produces excess hormones that cause symptoms. These symptoms can appear even when the tumor is small because the hormone, not the tumor size, is creating the problem. Common functional pNET types include:
- Insulinoma: Produces too much insulin, often causing low blood sugar, sweating, shakiness, confusion, hunger, weakness, or fainting.
- Gastrinoma: Produces excess gastrin, which can lead to severe acid reflux, stomach ulcers, abdominal pain, diarrhea, and a condition known as Zollinger-Ellison syndrome.
- Glucagonoma: Produces excess glucagon and may cause high blood sugar, weight loss, anemia, diarrhea, and a distinctive rash called necrolytic migratory erythema.
- VIPoma: Produces vasoactive intestinal peptide, often causing watery diarrhea, dehydration, low potassium, and weakness.
- Somatostatinoma: Produces somatostatin and may be linked with diabetes, gallstones, diarrhea, weight loss, or fatty stools.
Functional tumors are like tiny hormone factories that refuse to read the employee handbook. The symptoms can be strange, intense, and easy to mistake for more common conditions.
Nonfunctional Pancreatic NETs
Most pancreatic neuroendocrine tumors are nonfunctional. This means they do not release enough active hormone to cause a clear hormone-related syndrome. Because they may not cause early symptoms, they can grow quietly for years.
Nonfunctional pNETs are often discovered when imaging tests are done for another reason. When symptoms do appear, they are usually caused by the tumor’s size, location, or spread rather than hormone activity.
Well-Differentiated vs. Poorly Differentiated Tumors
Doctors also look at how the tumor cells appear under a microscope. A well-differentiated neuroendocrine tumor tends to look more like normal neuroendocrine tissue and may grow more slowly. A poorly differentiated neuroendocrine carcinoma is usually more aggressive and requires a different treatment approach.
Tumor Grade and Ki-67
Grade is another important part of the diagnosis. It describes how quickly the tumor cells appear to be growing. Pathology reports often include a marker called Ki-67, which estimates how many tumor cells are actively dividing. Lower-grade tumors usually grow more slowly, while higher-grade tumors may behave more aggressively.
Symptoms of Pancreatic Neuroendocrine Tumor
Symptoms depend on whether the tumor is functional or nonfunctional, where it is located in the pancreas, whether it has spread, and which hormones may be involved.
General Symptoms
Possible symptoms of pancreatic NETs include:
- Abdominal pain or discomfort
- Back pain
- Unexplained weight loss
- Loss of appetite
- Nausea or indigestion
- Diarrhea
- Fatigue
- A lump or fullness in the abdomen
- Yellowing of the skin or eyes, known as jaundice
- New or worsening blood sugar problems
Hormone-Related Symptoms
Functional pancreatic NET symptoms can look very different depending on the hormone involved. For example, an insulinoma may cause episodes of low blood sugar that improve after eating. A gastrinoma may cause stubborn ulcers or acid reflux that laughs in the face of ordinary antacids. A VIPoma may cause frequent watery diarrhea that leads to dehydration. A glucagonoma may cause diabetes-like symptoms, weight loss, and a rash.
Because these symptoms overlap with many everyday conditions, people may see several specialists before the dots are connected. That does not mean the symptoms are “all in your head.” It means the pancreas is very good at being mysterious.
Causes and Risk Factors
For many people, the exact cause of a pancreatic neuroendocrine tumor is unknown. These tumors happen when changes in cell DNA allow neuroendocrine cells to grow in an abnormal way. Most cases are not clearly inherited, but some are linked with genetic syndromes.
Risk factors and related conditions may include:
- Multiple endocrine neoplasia type 1: Also called MEN1, this inherited syndrome increases the risk of tumors in endocrine glands, including the pancreas.
- Von Hippel-Lindau disease: A hereditary condition that can increase the risk of several tumor types.
- Neurofibromatosis type 1: A genetic disorder that may be associated with certain neuroendocrine tumors.
- Tuberous sclerosis complex: A rare inherited condition that can cause noncancerous and cancerous growths in different organs.
- Family history: A personal or family history of endocrine tumors may raise suspicion for an inherited syndrome.
Having a risk factor does not mean someone will develop a pNET. Not having risk factors does not make it impossible. Cancer biology enjoys ignoring our desire for neat categories.
How Pancreatic NETs Are Diagnosed
Diagnosing a pancreatic neuroendocrine tumor usually requires a combination of medical history, physical exam, blood tests, imaging, and sometimes biopsy. No single test answers every question.
Blood and Urine Tests
If a functional tumor is suspected, doctors may check hormone levels such as insulin, gastrin, glucagon, vasoactive intestinal peptide, somatostatin, glucose, or other related markers. Some patients may also have tests for chromogranin A, although results can be affected by medications and other conditions.
Imaging Tests
Imaging helps locate the tumor and see whether it has spread. Common tests include CT scans, MRI, endoscopic ultrasound, and specialized nuclear medicine scans. Somatostatin receptor imaging, such as DOTATATE PET scanning, can be especially useful for many well-differentiated neuroendocrine tumors because these tumors often have somatostatin receptors on their surface.
Biopsy and Pathology
A biopsy may be done to confirm the diagnosis and determine tumor grade. Endoscopic ultrasound can help guide a biopsy needle into the pancreas. The pathology report may describe whether the tumor is well-differentiated, its grade, mitotic rate, Ki-67 index, and other details that guide treatment.
Treatment Options
Treatment for pancreatic NET depends on the tumor’s size, grade, location, symptoms, whether it has spread, and the patient’s overall health. Care is often best handled by a multidisciplinary team that may include surgical oncologists, medical oncologists, endocrinologists, gastroenterologists, radiologists, pathologists, nuclear medicine specialists, dietitians, and supportive care professionals.
Surgery
Surgery may offer the best chance for long-term control or cure when the tumor is localized and can be removed safely. The type of surgery depends on where the tumor sits in the pancreas. Options may include removing part of the pancreas, removing the pancreatic tail, performing a Whipple procedure for tumors in the pancreatic head, or removing nearby lymph nodes. Some small, low-risk tumors may be monitored carefully instead of removed right away.
Somatostatin Analogs
Medicines such as octreotide or lanreotide may help control hormone-related symptoms and slow tumor growth in certain cases. These drugs can be especially useful for tumors with somatostatin receptors.
Targeted Therapy
Targeted drugs may be used for advanced pancreatic NETs. These treatments are designed to interfere with specific pathways cancer cells use to grow. They are not “easy buttons,” but they can be valuable tools when surgery is not enough or is not possible.
Peptide Receptor Radionuclide Therapy
Peptide receptor radionuclide therapy, often called PRRT, delivers radiation directly to tumor cells that express somatostatin receptors. It may be considered for certain advanced or progressive neuroendocrine tumors after specialized imaging confirms receptor activity.
Liver-Directed Treatments
The liver is a common site for pancreatic NET spread. When liver metastases are present, treatment may include ablation, embolization, radioembolization, surgery, systemic therapy, or combinations of these approaches.
Chemotherapy
Chemotherapy may be used for some higher-grade, fast-growing, or advanced pancreatic neuroendocrine tumors. The role of chemotherapy varies depending on tumor biology, grade, and prior treatments.
Outlook and Survival
The outlook for a pancreatic neuroendocrine tumor varies widely. Some people live many years with slow-growing disease, while others have aggressive tumors that need urgent treatment. Important factors include stage, grade, tumor size, whether the tumor can be removed, hormone activity, liver involvement, overall health, and response to treatment.
In general, localized pancreatic NETs have a much better prognosis than tumors that have spread to distant organs. Recent U.S. cancer statistics show much higher five-year relative survival for localized pNETs than for distant-stage disease. However, survival statistics describe groups, not individuals. They cannot predict exactly what will happen to one person sitting in one exam room with one very specific tumor.
A helpful way to think about prognosis is this: stage tells where the tumor is, grade tells how fast it may be moving, and treatment response tells how well the plan is working. All three matter.
Living With a Pancreatic Neuroendocrine Tumor
Living with a pNET often means learning a new medical vocabulary while trying to keep normal life from falling off the kitchen counter. Patients may need regular scans, lab tests, symptom tracking, nutrition support, medication adjustments, and follow-up visits. It can be a lot.
Practical steps may include keeping a symptom diary, writing down questions before appointments, asking for copies of pathology and imaging reports, and learning the tumor’s grade and stage. Patients should also tell their care team about new symptoms such as worsening pain, jaundice, severe diarrhea, repeated low blood sugar, black stools, sudden weight loss, or dehydration.
Nutrition can become important, especially if the pancreas is not making enough digestive enzymes or if treatment affects appetite. Some people benefit from smaller meals, hydration plans, pancreatic enzyme replacement, blood sugar monitoring, or help from a registered dietitian. The best plan is personal, not copied from someone’s cousin’s Facebook comment section.
When to Seek Medical Attention
Anyone with persistent abdominal pain, unexplained weight loss, recurring low blood sugar, severe diarrhea, jaundice, new digestive problems, or unusual hormone-related symptoms should seek medical care. These symptoms do not automatically mean cancer, but they deserve attention.
People already diagnosed with a pancreatic neuroendocrine tumor should contact their healthcare team promptly if symptoms change suddenly or become severe. Fast communication can prevent complications and help treatment stay on track.
Experiences and Real-Life Lessons Related to Pancreatic Neuroendocrine Tumor
Although every pancreatic neuroendocrine tumor journey is different, many patients describe a similar emotional pattern: confusion first, information overload second, and then a slow shift toward becoming their own organized health advocate. At the beginning, the diagnosis may feel strange because pNETs are rare and less familiar than other cancers. Some people have never heard the phrase “neuroendocrine tumor” until the day it appears on a scan report. That can make the experience feel isolating, even before treatment begins.
One common experience is delayed recognition. A person with an insulinoma may have months of shakiness, sweating, and brain fog before anyone realizes the episodes are caused by low blood sugar. Someone with a gastrinoma may be treated repeatedly for ulcers or reflux. A person with a nonfunctional pNET may feel mostly fine until a scan for kidney stones, back pain, or another unrelated issue reveals a pancreatic mass. The diagnosis can arrive like an unexpected guest who did not call first and definitely did not bring snacks.
Patients often learn that asking specific questions helps. Instead of only asking, “Is it bad?” more useful questions include: What is the tumor grade? Is it functional or nonfunctional? Has it spread? Is surgery possible? What does the Ki-67 number mean in my case? Should I have genetic counseling? Do I need somatostatin receptor imaging? How often will scans be repeated? These questions help turn a frightening label into a clearer plan.
Another shared experience is the importance of specialized care. Because pancreatic NETs are uncommon, many patients benefit from evaluation at a center familiar with neuroendocrine tumors. This does not mean every person needs the most aggressive treatment right away. In fact, some small, slow-growing tumors may be watched carefully. But expert review can help prevent both undertreatment and overtreatment, which is a very medical way of saying, “Let’s not use a sledgehammer when a screwdriver will do.”
Daily life may also change in practical ways. People with hormone-producing tumors may need to plan meals, monitor blood sugar, manage diarrhea, stay hydrated, or carry emergency snacks. Those receiving injections, targeted therapy, chemotherapy, or PRRT may plan life around treatment cycles and follow-up scans. Scan anxiety is real; many patients feel tense before imaging and calmer once results are explained. Support groups, counseling, patient education organizations, and honest conversations with loved ones can make the waiting periods easier.
For caregivers, the experience often involves balancing encouragement with logistics. Driving to appointments, tracking medications, helping with meals, and remembering questions can be just as meaningful as giving a pep talk. For patients, accepting help can be hard, especially for people used to being independent. Still, cancer care is not a solo sport. Even the strongest person deserves a bench, a coach, and someone who knows where the parking garage ticket went.
The biggest lesson from many pNET experiences is that the diagnosis is not the whole story. Tumor type, grade, stage, symptoms, treatment options, and personal goals all shape the path forward. A pancreatic neuroendocrine tumor can be serious, but it is also a condition with multiple treatment strategies and a growing base of medical knowledge. The most empowering step is to gather accurate information, build a skilled care team, and take the process one decision at a time.
Conclusion
A pancreatic neuroendocrine tumor is a rare tumor that begins in the hormone-producing cells of the pancreas. It may be functional, causing hormone-related symptoms, or nonfunctional, growing silently until it causes pressure, pain, jaundice, or is found on imaging. Diagnosis usually involves blood tests, advanced imaging, biopsy, and pathology details such as grade and Ki-67. Treatment may include surgery, monitoring, somatostatin analogs, targeted therapy, PRRT, chemotherapy, or liver-directed procedures.
The outlook depends on the tumor’s stage, grade, location, spread, and response to treatment. While the diagnosis can feel overwhelming, many people with pancreatic NETs have meaningful treatment options. The smartest next step is not panic; it is a clear conversation with an experienced medical team.
